Chelsea Therapeutics (CHTP) tumbles 23% after the FDA asks for an additional study to show the...

|About: Chelsea Therapeutics Inte... (CHTP)|By:, SA News Editor

Chelsea Therapeutics (CHTP) tumbles 23% after the FDA asks for an additional study to show the durability of the company's Northera drug over a 2-3 month period. The request comes despite an agency panel recommending approval of Northera, which is designed to help stop patients with conditions like Parkinson's disease from tumbling.